Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04062708 · ClinicalTrials.gov registry record · Phase 2

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

A Phase 2 study of Stage IIIB Non-small Cell Lung Cancer and Stage IIIA Non-Small Cell Lung Cancer, sponsored by Alliance Foundation Trials.

Active
Registry status
Phase 2
Development phase
38
Enrollment target
9
Study locations

NCT04062708: Active Phase 2 study of Stage IIIB Non-small Cell Lung Cancer and Stage IIIA Non-Small Cell Lung Cancer, sponsored by Alliance Foundation Trials.

NCT04062708 is a Phase 2 study of Stage IIIB Non-small Cell Lung Cancer and Stage IIIA Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Alliance Foundation Trials. The registered enrollment target is 38 participants, below the 46-participant average among 16 other Stage IIIB Non-small Cell Lung Cancer trials with a reported enrollment target (17% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04062708, a Phase 2 study of Stage IIIB Non-small Cell Lung Cancer and Stage IIIA Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Alliance Foundation Trials.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
38 participants
Enrollment target
9
Study locations

Study Summary

This is a single arm, phase II trial of combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles for patients with potentially resectable stage IIIA and IIIB (T1-3, N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study is to increase N2 nodal clearance (N2NC) to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction therapy from historical rate of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage IIIA/B (N2) NSCLC.

Primary Outcome

To increase N2 nodal clearance (N2NC) to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction from an historical rate of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage IIIA/B (N2) NSCLC.

Conditions Studied

Stage IIIB Non-small Cell Lung Cancer Stage IIIA Non-Small Cell Lung Cancer

Interventions

  • RADIATION Radiotherapy
  • PROCEDURE Surgery
  • DRUG Durvalumab

Study Locations (9)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Brigham and Women's Hospital - Boston
  • Lowell General Hospital - Lowell

Illinois

  • NorthWestern University - Chicago
  • University of Chicago Medical Center - Chicago

New York

  • SUNY Upstate Medical University - Syracuse

Tennessee

  • Baptist Cancer Center - Memphis

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Virginia

  • University of Virginia Health System - Charlottesville

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2021-03-10
Est. Completion 2026-07
Phase Phase 2
Alliance Foundation Trials

20 total trials

What the registry record for NCT04062708 still lists

NCT04062708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 46-participant average among 16 other Stage IIIB Non-small Cell Lung Cancer trials with a reported enrollment target (17% lower).

The record links to 2 conditions, with Stage IIIB Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Radiotherapy is the first listed.

NCT04062708 lists 9 locations in 6 states (Massachusetts, Illinois, New York).

Frequently Asked Questions

What is clinical trial NCT04062708 about?

NCT04062708 is a clinical study titled "CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer". This is a single arm, phase II trial of combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles for patients with potentially resectable stage IIIA and IIIB (T1-3, N2) NSCLC (per the 8th International Assoc...

What is the current status of trial NCT04062708?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2021-03-10. Estimated completion is 2026-07.

What conditions does trial NCT04062708 study?

This clinical trial studies the following conditions: Stage IIIB Non-small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT04062708?

The interventions under investigation include: Radiotherapy (RADIATION), Surgery (PROCEDURE), Durvalumab (DRUG).

Who is sponsoring clinical trial NCT04062708?

This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04062708 being conducted?

This trial has 9 study locations across Illinois, Massachusetts, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IIIB Non-small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04062708's enrollment target sits among peer trials

38 10th of 16 higher than 7 of 16 other Stage IIIB Non-small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IIIB Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04062708, the US trial registry maintained by the National Library of Medicine. NCT04062708 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.